At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 226 enrolled
Drug / intervention
Pemetrexed 500 mg/m2 +1 moredrug
Likely dose
Pemetrexed 500 mg/m2 or 1000 mg/m2 intravenously every 21 days for one yearAI-extracted
Key inclusion· 3
- ✓Clinical stage III or IV non-small cell lung cancer
- ✓Prior treatment with one or two chemotherapy regimens
- ✓ECOG performance status 0, 1, or 2
Key exclusion· 1
- ✕Unable or unwilling to take folic acid or vitamin B12 supplementation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial
In Brief
A Phase 2 clinical trial evaluating Pemetrexed 500 mg/m2 and Pemetrexed 1000 mg/m2 for Non-small Cell Lung Cancer. Completed, enrolled 226 participants across 16 sites.
Detailed Summary
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedSep 2005
Primary CompletionOct 2008
TodayJul 2026
First PostedSep 19, 2005
Enrollment StartOct 1, 2004
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.8 years ago
Interventions
Pemetrexed 500 mg/m2drug
500 mg/m2, intravenous (IV), every 21 days, one year from registration date
Pemetrexed 1000 mg/m2drug
1000 mg/m2, intravenous (IV), every 21 days, one year from registration date